Covid-19 Innovation Challenges by Innoget

SARS-CoV-2 NSP16 Targeted Library

Posted by Covid-19 Innovation Challenges by InnogetVery responsive · Innovative Products and Technologies · United Kingdom

Send your request

Summary of the technology

SARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library, which contains 1049 compounds with predicted activity against SARS-CoV-2 NSP16 is offered. The library has been designed with receptor-based virtual screening using crystal structure of SARS-CoV-2 2′-O-MTase (PDB ID: 6WKQ).

Covid-19 Innovation Challenges by Innoget

Description of the technology

2′-O-methyltransferase (2′-O-MTase, non-structural protein 16, nsp16) can act as potential drug target for the SARS-CoV-2. It prevents recognition and activation of the host immune response which is essential for successful viral infection. OTAVAchemicals offers SARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library (1049 compounds with predicted activity against SARS-CoV-2 NSP16). The library has been designed with receptor-based virtual screening using crystal structure of SARS-CoV-2 2′-O-MTase (PDB ID: 6WKQ). The overall procedure included accurate flexible docking of Drug-like Green Collection into methyltransferase catalytic site. Final selection of compounds was made with inspection of enzyme active site’s crucial structural determinants for ligand binding, docking scores and intermolecular hydrogen bonds with key active site’s amino acid residues.

Technology Owner

Covid-19 Innovation Challenges by Innoget

Innovation Intermediary

Related keywords

  • Applications for Health
  • Biological Sciences
  • Medicine, Human Health
  • Biostatistics, Epidemiology
  • Diagnostics, Diagnosis
  • Medical Research
  • Virus, Virology / Antibiotics / Bacteriology
  • Biology / Biotechnology
  • Infectious Diseases
  • Medical/health
  • Medical Health related
  • Diagnostic
  • Diagnostic services
  • Other Medical/Health Related
  • Covid-19
  • coronavirus
  • sars-cov-s

About Covid-19 Innovation Challenges by Innoget

Innovation Intermediary from United Kingdom

Ahead of the current Coronavirus outbreak, Innoget is fully committed to contributing to mobilizing scientific and expert communities to find a real solution to the Covid-19 pandemic. Therefore, we're supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Channeled through Innoget's online open innovation network, initiatives in the health, virology, medicine, or novel technologies applied to human health, among others, are listed and disseminated to Innoget members -ranging from hospitals, research institutes, scientists, businesses, and public administrations- and innovation partners worldwide.

Similar Technology Offers

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors
  • +6 months
  • Hide post

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors
  • +6 months
  • Hide post

Expertise in molecular biology either experimentally or computationally

The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Expertise in molecular biology either experimentally or computationally
  • +6 months
  • Hide post

Expertise in molecular biology either experimentally or computationally

The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Expertise in molecular biology either experimentally or computationally
  • +6 months
  • Hide post

COVID-19 Rapid Diagnostic Kit

Designing and developing vaccines, cures and diagnostic kits can be considered as the first priority for every country which is in the first line of fighting against coronavirus. Now there is only PCR test and IgG/IgM test for COVID-19 assessment. One of the most important problems of this diagnostic test is the time needed by the device to detect infected persons. This problem makes big companies in the field of pharmaceutical and medical devices manufacturing to design and develop rapid test kits. Our research team found that there are some specific proteins on the viral membrane which can make some reagents undergo a specific chemical reaction. Every reaction has a specific product related to substrates, so by detection of products with indicator reagents we are able to identify the virus in saliva. Indicator reagents usually change the reaction mixture color so by color change we can approve that the person is infected by COVID-19. The advantages of using saliva include: specimen collection can be done without a healthcare professional no additional equipment such as swabs or transport media are needed as nasopharyngeal specimens can be 'uncomfortable' use of saliva-based testing may encourage recruits to clinical trials of vaccines. So far two prototypes have been designed: 1) For Home Testing: Disposable test kits where an individual adds a saliva sample into a vial containing the indicator reagent, the presence of the COVID-19 virus is indicated by a positive test as shown by a colour change. 2) Reusable Low Cost Test Kits for Healthcare Professionals: Where there is a low concentration of virus in saliva, for example in the first days after infection, viral proteins can be concentrated using a saliva condensation function. In this situation, multiple samples of saliva are placed into a device which can condensate the samples to increase concentration of any virus present. After the test has been completed, the vessel can be disinfected for ready for re-use. One of the most important properties of this approach is a much lower error rate than has been found in other devices. (errors found in other tests are in various submitted articles to different journals). The re-usable nature of this professional test could make it a practical solution for low-income countries where large scale expensive PCR testing is not an option.

COVID-19 Rapid Diagnostic Kit
  • +6 months
  • Hide post

View other related tech offers

Submit your request
Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Other users also viewed

COVID-19 Rapid Diagnostic KitShimmer3 Bioimpedance Monitor - Monitoring HR, respiration rate and depth, and the increase in fluid in the lungs to triage and remotely monitor Covid-19 patientsShimmer3 Bioimpedance Monitor - Monitoring HR, respiration rate and depth, and the increase in fluid in the lungs to triage and remotely monitor Covid-19 patientsTesting of drugs against SARS-CoV-2Deciphering the Virus-Host Tango: Understanding network of interactions through evolution, structure, dynamics, and computational design